CDNA
CareDx, Inc NASDAQ Listed Jul 17, 2014$21.42
Mkt Cap $1.1B
52w Low $10.96
85.2% of range
52w High $23.24
50d MA $18.70
200d MA $16.90
P/E (TTM)
-53.8x
EV/EBITDA
-1436.6x
P/B
3.8x
Debt/Equity
0.1x
ROE
-2.6%
P/FCF
27.8x
RSI (14)
—
ATR (14)
—
Beta
2.54
50d MA
$18.70
200d MA
$16.90
Avg Volume
704.3K
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
1 Tower Place · South San Francisco, CA 94080 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 28, 2026 | AMC | 0.11 | 0.34 | +209.1% | 21.91 | +2.1% | -5.1% | +0.0% | +3.3% | -2.5% | -1.2% | — |
| Feb 24, 2026 | AMC | 0.02 | 0.12 | +503.0% | 19.25 | -11.3% | -4.1% | +2.0% | -0.3% | -0.1% | +0.3% | — |
| Nov 4, 2025 | AMC | 0.13 | 0.28 | +115.4% | 14.52 | +8.5% | +13.8% | -9.2% | +4.1% | +6.9% | +0.5% | — |
| Aug 6, 2025 | AMC | 0.12 | 0.10 | -16.7% | 13.10 | -7.5% | -7.9% | -0.8% | -1.7% | +5.9% | -2.6% | — |
| Apr 30, 2025 | AMC | 0.06 | 0.09 | +50.0% | 16.88 | -3.4% | -10.7% | -0.5% | +1.1% | -6.5% | +4.2% | — |
| Feb 26, 2025 | AMC | 0.05 | 0.18 | +260.0% | 21.10 | +6.1% | -0.2% | +5.2% | -4.6% | -3.9% | +0.6% | — |
| Nov 4, 2024 | AMC | 0.01 | 0.14 | +1300.0% | 22.93 | -7.1% | -0.1% | +1.4% | +2.9% | -1.0% | -1.3% | — |
| Jul 31, 2024 | AMC | -0.13 | 0.25 | +292.3% | 19.99 | +30.1% | +18.0% | -3.0% | +3.5% | +5.6% | -2.9% | — |
| May 9, 2024 | AMC | -0.19 | -0.03 | +84.2% | 11.06 | +14.2% | +34.1% | +1.0% | +1.7% | -3.0% | +0.0% | — |
| Feb 28, 2024 | AMC | -0.24 | -0.17 | +29.2% | 9.72 | +0.1% | +9.5% | +12.9% | +0.6% | -4.0% | +1.0% | — |
| Nov 8, 2023 | AMC | -0.38 | -0.18 | +52.6% | 6.33 | +26.4% | +13.9% | +2.8% | +6.9% | +12.2% | +1.7% | — |
| Aug 8, 2023 | AMC | -0.42 | -0.18 | +57.1% | 11.04 | +3.4% | -11.2% | -1.2% | -8.1% | +5.0% | +3.4% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 29 | BTIG | Maintains | Buy → Buy | — | $21.91 | $22.37 | +2.1% | -5.1% | +0.0% | +3.3% | -2.5% | -1.2% |
| Feb 26 | BTIG | Maintains | Buy → Buy | — | $18.46 | $18.79 | +1.8% | +2.0% | -0.3% | -0.1% | +0.3% | +1.4% |
| Feb 25 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $19.25 | $17.08 | -11.3% | -4.1% | +2.0% | -0.3% | -0.1% | +0.3% |
| Dec 15 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $20.56 | $20.61 | +0.2% | -3.2% | -2.8% | +0.7% | -1.5% | +1.4% |
| Nov 6 | BTIG | Maintains | Buy → Buy | — | $16.53 | $16.46 | -0.4% | -9.2% | +4.1% | +6.9% | +0.5% | -2.8% |
| Sep 23 | BTIG | Maintains | Buy → Buy | — | $14.99 | $15.12 | +0.9% | +3.9% | -3.3% | -1.3% | +0.4% | -0.5% |
| Sep 12 | BTIG | Maintains | Buy → Buy | — | $13.53 | $13.40 | -1.0% | +0.0% | +3.6% | +1.1% | +0.8% | +3.3% |
| Aug 8 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $12.07 | $12.10 | +0.2% | -0.8% | -1.7% | +5.9% | -2.6% | -2.6% |
| Jul 18 | Craig-Hallum | Maintains | Buy → Buy | — | $11.81 | $12.31 | +4.2% | +0.9% | +7.0% | +2.1% | +0.8% | -2.1% |
| May 5 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $15.00 | $14.70 | -2.0% | +1.1% | -6.5% | +4.2% | +4.2% | -0.2% |
| May 5 | Stephens & Co. | Maintains | Overweight → Overweight | — | $15.00 | $14.70 | -2.0% | +1.1% | -6.5% | +4.2% | +4.2% | -0.2% |
| Apr 17 | Goldman Sachs | Maintains | Buy → Buy | — | $18.22 | $18.17 | -0.3% | -3.3% | -3.9% | +4.9% | +0.4% | +3.6% |
| Mar 3 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $22.15 | $21.78 | -1.7% | -4.6% | -3.9% | +0.6% | -7.4% | +0.1% |
| Feb 27 | Stephens & Co. | Maintains | Overweight → Overweight | — | $21.10 | $22.38 | +6.1% | -0.2% | +5.2% | -4.6% | -3.9% | +0.6% |
| Jan 15 | Wells Fargo | Upgrade | Underweight → Equal Weight | — | $22.05 | $23.35 | +5.9% | +2.9% | -2.8% | -2.8% | +5.9% | +2.2% |
| Jan 14 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $25.07 | $25.30 | +0.9% | -12.0% | +2.9% | -2.8% | -2.8% | +5.9% |
| Nov 5 | BTIG | Maintains | Buy → Buy | — | $22.93 | $21.31 | -7.1% | -0.1% | +1.4% | +2.9% | -1.0% | -1.3% |
| Oct 16 | Goldman Sachs | Maintains | Buy → Buy | — | $26.35 | $26.41 | +0.2% | -0.6% | -6.5% | -2.0% | -2.1% | -1.4% |
| Aug 19 | BTIG | Upgrade | Neutral → Buy | — | $33.00 | $33.53 | +1.6% | +3.0% | -4.5% | +2.8% | -7.2% | +1.9% |
| Aug 1 | Craig-Hallum | Maintains | Buy → Buy | — | $19.99 | $26.00 | +30.1% | +18.0% | -3.0% | +3.5% | +5.6% | -2.9% |
| Aug 1 | Goldman Sachs | Maintains | Buy → Buy | — | $19.99 | $26.00 | +30.1% | +18.0% | -3.0% | +3.5% | +5.6% | -2.9% |
| Jul 17 | Goldman Sachs | Maintains | Buy → Buy | — | $18.57 | $17.70 | -4.7% | -1.5% | -0.9% | -0.3% | +4.3% | +0.7% |
| May 17 | Craig-Hallum | Maintains | Buy → Buy | — | $14.78 | $15.30 | +3.5% | +4.9% | +0.8% | -3.2% | +2.9% | +1.7% |
| May 13 | Stephens & Co. | Maintains | Overweight → Overweight | — | $14.83 | $14.95 | +0.8% | +1.0% | +1.7% | -3.0% | +0.0% | +4.9% |
| May 13 | Goldman Sachs | Maintains | Buy → Buy | — | $14.83 | $14.95 | +0.8% | +1.0% | +1.7% | -3.0% | +0.0% | +4.9% |
| May 13 | Raymond James | Downgrade | Outperform → Market Perform | — | $14.83 | $14.95 | +0.8% | +1.0% | +1.7% | -3.0% | +0.0% | +4.9% |
| May 9 | Craig-Hallum | Maintains | Buy → Buy | — | $10.18 | $10.17 | -0.1% | +8.6% | +34.1% | +1.0% | +1.7% | -3.0% |
| May 1 | Craig-Hallum | Upgrade | Hold → Buy | — | $7.76 | $8.51 | +9.7% | +18.3% | +1.0% | +4.9% | +4.7% | +2.9% |
| Apr 17 | Stephens & Co. | Maintains | Overweight → Overweight | — | $7.85 | $7.98 | +1.7% | +5.5% | -2.5% | +3.0% | -1.7% | +0.7% |
| Nov 9 | Stephens & Co. | Upgrade | Equal Weight → Overweight | — | $6.33 | $8.00 | +26.4% | +13.9% | +2.8% | +6.9% | +12.2% | +1.7% |
| Sep 26 | Stephens & Co. | Maintains | Equal Weight → Equal Weight | — | $7.64 | $7.56 | -1.0% | -3.7% | +0.1% | -4.5% | -0.6% | -2.0% |
| Aug 15 | Raymond James | Upgrade | Market Perform → Outperform | — | $9.35 | $9.80 | +4.9% | +3.4% | -9.5% | -3.1% | -0.7% | +2.5% |
| Jul 11 | Raymond James | Maintains | Market Perform → Market Perform | — | $9.71 | $10.28 | +5.9% | +6.5% | +1.0% | -3.2% | -3.4% | +3.6% |
| May 11 | BTIG | Downgrade | Buy → Neutral | — | $8.59 | $6.45 | -24.9% | -2.7% | -3.7% | +3.6% | -6.8% | +0.0% |
| Mar 7 | Stephens & Co. | Downgrade | Overweight → Equal Weight | — | $10.65 | $9.53 | -10.6% | -0.4% | +0.7% | -6.0% | -5.1% | +2.7% |
| Mar 7 | Goldman Sachs | Maintains | Buy → Buy | — | $10.65 | $9.53 | -10.6% | -0.4% | +0.7% | -6.0% | -5.1% | +2.7% |
| Mar 3 | Raymond James | Downgrade | Strong Buy → Market Perform | — | $10.77 | $9.31 | -13.5% | -16.7% | +18.7% | -0.4% | +0.7% | -6.0% |
| Mar 3 | Craig-Hallum | Downgrade | Buy → Hold | — | $10.77 | $9.31 | -13.5% | -16.7% | +18.7% | -0.4% | +0.7% | -6.0% |
| Feb 28 | Craig-Hallum | Maintains | Buy → Buy | — | $14.71 | $15.00 | +2.0% | +14.3% | -4.9% | -32.7% | -16.7% | +18.7% |
| Feb 28 | BTIG | Maintains | Buy → Buy | — | $14.71 | $15.00 | +2.0% | +14.3% | -4.9% | -32.7% | -16.7% | +18.7% |
| Feb 28 | Goldman Sachs | Maintains | Buy → Buy | — | $14.71 | $15.00 | +2.0% | +14.3% | -4.9% | -32.7% | -16.7% | +18.7% |
| Feb 6 | Goldman Sachs | Maintains | Buy → Buy | — | $16.54 | $16.47 | -0.4% | -1.7% | +1.8% | -5.0% | -1.5% | -1.4% |
| Jan 31 | Raymond James | Maintains | Strong Buy → Strong Buy | — | $14.65 | $14.64 | -0.1% | +2.0% | +4.8% | +12.5% | -6.1% | -1.7% |
| Nov 8 | Raymond James | Maintains | Strong Buy → Strong Buy | — | $15.86 | $16.05 | +1.2% | +3.5% | -9.6% | -11.7% | +17.1% | -7.4% |
| Nov 7 | BTIG | Maintains | Buy → Buy | — | $16.02 | $16.29 | +1.7% | -1.0% | +3.5% | -9.6% | -11.7% | +17.1% |
| Nov 4 | Goldman Sachs | Maintains | Buy → Buy | — | $18.73 | $18.92 | +1.0% | -14.5% | -1.0% | +3.5% | -9.6% | -11.7% |
| Sep 2 | Stephens & Co. | Maintains | Overweight → Overweight | — | $20.31 | $20.77 | +2.3% | -9.7% | -4.9% | +6.0% | +1.2% | +2.6% |
| Aug 10 | Raymond James | Maintains | Strong Buy → Strong Buy | — | $23.48 | $24.32 | +3.6% | +6.9% | -8.4% | +3.0% | +2.5% | -7.2% |
| May 6 | Raymond James | Maintains | Strong Buy → Strong Buy | — | $31.66 | $30.36 | -4.1% | -18.6% | -12.9% | +3.0% | -6.2% | +8.0% |
| Apr 25 | Stephens & Co. | Maintains | Overweight → Overweight | — | $30.57 | $30.69 | +0.4% | +5.9% | -6.8% | +0.2% | +2.1% | -1.3% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 5, 2026 | Novack Jeffrey Adam | Secretary and General Counsel | Sell | 2,688 | $20.68 | $56K | 113,924 | +2.34% | — |
8-K · 5.02
!!! Very High
CareDx, Inc. -- 8-K 5.02: Executive Change
CareDx (CDNA) experienced an executive change, though specific leadership details weren't disclosed in this brief filing update, potentially signaling internal reorganization that investors should monitor for broader strategic implications.
Apr 23
8-K · 1.01
!! High
Unknown — 8-K 1.01: Material Agreement
CDNA's partnership with Eurobio Scientific expands its market reach in Europe for diagnostic products, potentially driving revenue growth and reducing geographic concentration risk.
Apr 16
8-K · 5.02
!!! Very High
CareDx, Inc. -- 8-K 5.02: Executive Change
CareDx appointed Keith Kennedy as principal financial officer, replacing Nathan Smith's resignation as CFO, signaling potential leadership transition and possible strategic shifts in financial management.
Feb 25
8-K · 5.02
!!! Very High
CareDx, Inc. -- 8-K 5.02: Executive Change
CareDx appointed Keith Kennedy as principal financial officer, replacing Nathan Smith who resigned, signaling potential leadership transition and strategic direction changes for the transplant diagnostics company.
Feb 24
Data updated apr 25, 2026 12:30am
· Source: massive.com